论文部分内容阅读
目的检测非小细胞肺癌患者的血清蛋白质谱,探讨非小细胞肺癌血清蛋白质指纹图与临床分期的关系,为非小细胞肺癌预后判断、临床治疗决策选择提供依据。方法共收集69例非小细胞肺癌患者血清,应用阳离子交换蛋白(CM10)芯片,通过表面增强激光解吸电离-飞行时间-质谱(SELDI-TOF-MS)技术检测非小细胞肺癌患者血清蛋白质质谱,应用生物信息学方法分析血清蛋白质指纹图与非小细胞肺癌临床分期的关系。结果比较28例Ⅰ～Ⅱ期与41例Ⅲ～Ⅳ期非小细胞肺癌蛋白指纹图,共筛选出68个有显著性差异的质荷比峰(m/z),最终筛选出2个潜在标志物5 632 m/z、13 779 m/z。5 632 m/z、13 779 m/z均在Ⅲ～Ⅳ期非小细胞肺癌中高表达,在Ⅰ～Ⅱ期非小细胞肺癌中低表达。将此标记物作为非小细胞肺癌分期模型,其正确指数为0.587,一致率为79.5%,Kappa=0.32。结论 SELDI-TOF-MS技术检测非小细胞肺癌患者血清蛋白质质谱,筛选出m/z位于5 632、13 779的蛋白质峰可能是非小细胞肺癌术前临床分期的标记物。
Objective To detect serum protein profiles in patients with non-small cell lung cancer (NSCLC) and to explore the relationship between serum protein fingerprints and clinical stage in non-small cell lung cancer (NSCLC) and to provide evidences for the prognosis and clinical decision-making of non-small cell lung cancer. Methods Seventy-nine patients with non-small cell lung cancer were enrolled in this study. Serum protein was detected by CMIS chip using SELDI-TOF-MS. Application of bioinformatics methods to analyze the relationship between serum protein fingerprints and clinical stage of non-small cell lung cancer. Results The protein fingerprints of 28 cases of stage Ⅰ-Ⅱ and 41 cases of stage Ⅲ-Ⅳ non-small cell lung cancer were compared. A total of 68 m / z peaks were screened out and 2 potential markers were screened out. 5 632 m / z, 13 779 m / z. 5 632 m / z and 13 779 m / z were all highly expressed in stage Ⅲ-Ⅳ non-small cell lung cancer and were low in stage Ⅰ-Ⅱ non-small cell lung cancer. Using this marker as a staging model for non-small cell lung cancer, the correct index was 0.587, the concordance rate was 79.5%, and Kappa = 0.32. Conclusion SELDI-TOF-MS was used to detect serum protein mass spectrum in patients with non-small cell lung cancer. Screening out protein peaks with m / z at 5 632 and 13 779 may be preoperative clinical stage markers for non-small cell lung cancer.